Heat Biologics rises 10% as Elusys finalizes HHS contract for anthrax antitoxin Anthim

Jan. 31, 2022 3:33 PM ETNightHawk Biosciences, Inc. (NHWK)By: Ravikash, SA News Editor
  • Elusys Therapeutics, which is being acquired by Heat Biologics (HTBX +9.9%), said it finalized a contract with the U.S. Department of Health and Human Services (HHS) for the continued supply of anthrax antitoxin Anthim (obiltoxaximab) for use against a potential anthrax attack.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.